Business Wire

PSA-CERTIFIED

4.4.2024 10:01:28 CEST | Business Wire | Press release

Share
PSA Certified Announces New PSA Certified Level 4 Certification and Continued Partner Growth

PSA Certified, the global security and evaluation framework for the connected device ecosystem, has today announced its highest certification level to date as it accelerates its mission to build assurance in connected devices. The new PSA Certified Level 4 iSE/SE certification offers enhanced protection of high value assets that can secure valuable AI models, future-proofing systems against new attack methods and rising security threats linked to the rapid adoption of edge AI. Its launch follows a period of strong momentum for PSA Certified which has become a trusted route for demonstrating security best practice and the assurance of connected devices.

David Maidment, Senior Director, Secure Devices Ecosystem at Arm (a PSA Certified co-founder):

As the world embraces a new set of AI-enabled use cases, the value of data and assets has never been higher; nor has the importance of protecting them. The launch of PSA Certified Level 4 iSE/SE is testament to our commitment to helping the industry deploy security features that will protect devices and models from malicious changes and theft now, as well as over the next decade.”

As security cements its position as a business imperative, forward-looking companies are uplevelling their investment in security-by-design. PSA Certified has now surpassed the milestone of 200 certifications from nearly 90 technology providers, making it one of the most successful schemes to address connected device security.

The newly launched PSA Certified Level 4 Integrated Secure Enclave / Secure Element (iSE/SE) certification, already available at PSA Certified Labs, builds on the scheme’s momentum further and underpins a step change that can be used to protect valuable models and data during device boot and at rest (when models reside in secure storage). The level recognizes the use of a highly robust integrated Secure Enclave (iSE) or Secure Element (SE) - that acts as a trusted subsystem to the full Root of Trust (PSA RoT). By safeguarding critical cryptographic functions and key storage, OEMs can now ask for a RoT with a trusted subsystem that offers a ‘high’ level of attack resistance.

Benefits of PSA Certified Level 4 iSE / SE Certification include:

Protecting ML models at rest with highly robust crypto and key storage

  • PSA Certified Level 4 iSE/SE considers more sophisticated attack methods in scope. Chips that achieve this new level could be used in an AI context to help protect valuable models and data at boot and rest: some chips will need protection from advanced fault injection and differential power analysis (up to and including EMFI, single laser and multi-glitching). PSA Certified Level 4 iSE/SE chips will also benefit from stronger cryptography of at least 128-bit strength. The new level offers a “high” level of protection of the PSA-RoT assets from physical or software attack.
  • A trusted subsystem that achieves PSA Certified Level 4 iSE/SE can be used through composition in a PSA Certified Level 3+SE certification of the full PSA RoT security functionality. The PSA Certified Level 3 document has been updated to allow this new certification level.

PSA Certified Level 4 iSE/SE will help protect emerging use cases from sophisticated security attacks

  • PSA Certified Level 4 iSE/SE offers additional security against more advanced attacks. Chips that offer this RoT provide a strong trust anchor that could be used to decrypt and verify OTA updates which help protect models in high-value systems.
  • Industrial and safety-critical use cases need to support system recovery and stronger authentication: re-establishing integrity, confidentiality and availability are fundamental when rebooting systems and deploying OTA updates when faults are found, or upgrades are required. PSA Certified iSE/SE also mandates higher strength cryptography, which protects against more sophisticated attacks.
  • Trust anchor for Edge AI and infrastructure chips, providing a “High” level of protection against physical and software attacks on critical assets that require a more robust Root of Trust to maintain system integrity.

A transparent certification scheme with a route to High, Substantial, and Basic levels of robustness and assurance, purpose-built for the SoC market

  • PSA Certified offers a variety of robustness levels to match the market’s needs, all specifically designed for the electronics industry. By allowing a trusted subsystem to be certified as a component, and that certificate reused as part of a complete PSA RoT many times, chip vendors benefit from significant time and cost savings.

The first partner to aim for the PSA Certified Level 4 iSE/SE standard is Infineon, showcasing its commitment to developing IoT devices to the highest security-by-design standards.

Erik Wood, Senior Director, IoT Secure MCU Products at Infineon comments:

“In the age of AI, the risks of insecurity are immense and increasing. I’ve backed PSA Certified since launch and I am impressed by its success in uniting the technology ecosystem around the common goal of improving trust and security within the connected device ecosystem, while aligning to emerging government standards and legislation. The launch of PSA Certified Level 4 iSE/SE takes that one step further. With this new level, the electronics industry is better able to protect against the growing advancement of attack methods driven by the explosion of machine learning, generative AI and LLM.”

About PSA Certified

PSA Certified is a global partnership of security-conscious companies who are proactively building security best practices into devices at scale. Our security framework and independent third-party evaluation scheme was originally spearheaded by Arm and six other security ecosystem leaders (and now maintained by Applus+ Laboratories, CAICT, ECSEC Laboratory, ProvenRun, Riscure, SGS Brightsight, Serma, TrustCB, and UL) providing the resources needed to build upon the Root of Trust.

PSA Certified has scaled to become one of the fastest growing, most valued security ecosystems, globally. Being awarded ‘Ecosystem of the Year’ in the IoT Global Awards 2021 is testament to the role it has played in uniting industry, standards bodies, regulators and insurers together under one initiative. In doing so it’s accelerating the cross-industry collaboration required to untap the full potential of the IoT.

With 200 certifications from 88 partners, PSA Certified has democratized the adoption of security across the electronics industry, giving the ecosystem the confidence to innovate, while protecting consumers from the most common hacks.

Find out more: psacertified.org

1A Certified Security Report 2023

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240404517921/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye